Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and ...

Amgen loses $400 million antitrust battle to Regeneron

And more biotech news brought to you by The Readout.

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and the FDA scheduled an advisory meeting.

Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market

Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments - Regeneron Pharmaceuticals (NASDAQ:REGN)

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market Jury awarded Regeneron $135.6 million dollars of compensatory damages and $271.2 million dollars in punitive damages TARRYTOWN, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) applauds the jury verdict in the U.S. District Court f…

Regeneron scores $400M+ jury win in Amgen cholesterol drug spat

A Delaware jury on Thursday said Regeneron should get more than $400 million in damages in its long-running antitrust case against Amgen. Regeneron brought the case almost three years ago alleging ...

BREAKING: Regeneron Wins $271.2M in Antitrust Suit Against Amgen - USA Herald

In a significant legal victory, Regeneron Pharmaceuticals Inc. has won a $271.2 million punitive damages award from a federal jury in Delaware, concluding a closely watched antitrust suit against rival pharmaceutical giant Amgen Inc. The jury found that Amgen engaged in anti-competitive conduct by bundling its cholesterol-lowering drug Repatha with rebate incentives tied to two